Collaborations

	Silicos NV and reMYND NV announce a renewed collaboration. Silicos NV will apply its Spectrophores™ technology and Multi-Target screening platform to predict selectivity profiles for a series of lead compounds of reMYND NV in the field of neurodegenerative diseases. This is part of an effort to validate the molecular binding targets of these series.
	UCB and Silicos entered into a collaboration in the framework of early-phase drug discovery projects. Silicos' technology will be used for building predictive models for hit identification as well as lead optimization purposes.
	Silicos and Lead Pharma Holding BV are partners in the EuroTransBio project 3DHeartscreen.
	Silicos and Virtual Proteins BV are partners in the EuroTransBio project 3DHeartscreen.
	Movetis and Silicos entered into a collaboration based on the potential of Silicos' technology for building predictive models. The goal of the project is to train a specific model, using the Spectrophores™ technology, for the prediction of the steady state blood plasma ratio for chemical entities.
In Silico Biosciences	In Silico Biosciences has engaged Silicos in a multi-target virtual screening experiment to search for small molecule compounds that show desired activities against a panel of undisclosed targets. Silicos will apply its Spectrophores™ technology to build reliable virtual screening models for each of the targets and combine the models to find compounds with the expected activity profile.
CD³	Silicos NV and the Center for Drug Design and Discovery (CD3) of the Katholieke Universiteit Leuven teamed up to start a research collaboration. The focus of CD3 is on the discovery of new small molecules that interact with and modify the function of specific innovative targets or diseases and on the hit-to-lead-development of identified hit compounds, and this in collaboration with academic research groups or spin-off companies. Silicos will apply its expertise in computational drug discovery and chemoinformatics to assist the development of these drug discovery projects of CD3.
	Tigenix and Silicos have entered into a research collaboration focussing on the in silico analysis for identification of small molecules to modulate the activity of an undisclosed target and associated pathway for the treatment of osteo-arthritis.
	Silicos NV applied its Spectrophores™ technology to identify new compounds from its in-house compound database. The virtual screening experiment was based on a naive Bayesian classifier built from a set of moderately to highly active compounds previously identified by reMYND NV. After screening the entire database with the trained model, 100 compounds were selected from the top 2000, and subsequently screened by reMYND NV using their cell-based proprietary assays. Nearly 50% of the selected compounds showed micro- to sub-nanomolar activity.
	VIB and Silicos have started a collaboration to apply Silicos' Spectrophores™ technology in several research projects. The goal is to find small molecules that will modulate the activity of undisclosed targets that are under investigation in the different research teams of the VIB.
	Silicos N.V. and Vivactis NV have received a grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) to set up a joint project to evaluate the possible synergy between the proprietary technologies of both companies within the framework of drug discovery. The resulting innovative collaboration is focused on the use of experimental thermodynamic data in Cosmos™ to design new lead molecules for specific targets.